Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. 2021. CA: a cancer journal for clinicians. 2021;71(1):7–33.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424.
PubMed
Google Scholar
Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol. 2021;160(1):175–81.
Article
CAS
PubMed
Google Scholar
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet (London England). 2019;393(10177):1240–53.
Article
PubMed
Google Scholar
Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J Ovarian Res. 2019;12.
Prat J. New insights into ovarian cancer pathology. Annals of oncology: official journal of the European Society for Medical Oncology. 2012;23(Suppl 10):x111–117.
Article
PubMed
Google Scholar
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9.
Article
PubMed
Google Scholar
Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8.
Article
PubMed
Google Scholar
Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42(7):918–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131(1):52–8.
Article
CAS
PubMed
Google Scholar
Watanabe T, Nanamiya H, Endo Y, Kojima M, Nomura S, Furukawa S, et al. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. J Ovarian Res. 2021;14(1):129.
Article
CAS
PubMed
PubMed Central
Google Scholar
Saleh A, Perets R. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy. Cancers (Basel). 2021;13(14).
Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim et Biophys acta Reviews cancer. 2021;1875(2):188503.
Article
CAS
Google Scholar
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28.
Article
PubMed
PubMed Central
Google Scholar
Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev anticancer therapy. 2017;17(9):827–39.
Article
CAS
Google Scholar
Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clin Chim acta; Int J Clin Chem. 2015;446:147–55.
Article
CAS
Google Scholar
Ebbesen KK, Hansen TB, Kjems J. Insights into circular RNA biology. RNA Biol. 2017;14(8):1035–45.
Article
PubMed
Google Scholar
Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J, et al. The emerging landscape of circular RNA in life processes. RNA Biol. 2017;14(8):992–9.
Article
PubMed
Google Scholar
Ouyang Q, Huang Q, Jiang Z, Zhao J, Shi GP, Yang M. Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis. Mol Immunol. 2018;101:531–8.
Article
CAS
PubMed
Google Scholar
Huang Z, Su R, Qing C, Peng Y, Luo Q, Li J. Plasma Circular RNAs hsa_circ_0001953 and hsa_circ_0009024 as Diagnostic Biomarkers for Active Tuberculosis. Front Microbiol. 2018;9:2010.
Article
PubMed
PubMed Central
Google Scholar
Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, et al. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis. 2020;41(3):296–302.
Article
CAS
PubMed
Google Scholar
Liu XX, Yang YE, Liu X, Zhang MY, Li R, Yin YH, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med. 2019;17(1):50.
Article
PubMed
PubMed Central
Google Scholar
Ding J, Wang Q, Guo N, Wang H, Chen H, Ni G, et al. CircRNA circ_0072995 promotes the progression of epithelial ovarian cancer by modulating miR-147a/CDK6 axis. Aging (Albany NY). 2020;12(17):17209–23.
Article
CAS
PubMed
Google Scholar
Gan X, Zhu H, Jiang X, Obiegbusi SC, Yong M, Long X, et al. CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a. Mol cancer. 2020;19(1):45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu N, Zhang J, Zhang LY, Wang L. CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2018;22(12):3713–8.
CAS
PubMed
Google Scholar
Hu Y, Zhu Y, Zhang W, Lang J, Ning L. Utility Of Plasma circBNC2 As A Diagnostic Biomarker In Epithelial Ovarian Cancer. OncoTargets and therapy. 2019;12:9715–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ning L, Long B, Zhang W, Yu M, Wang S, Cao D, et al. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. Int J Oncol. 2018;53(6):2637–46.
CAS
PubMed
Google Scholar
Ning L, Lang J, Wu L. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer. BMC Cancer. 2022;22(1):6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih Ie M, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011;122(3):560–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hang D, Zhou J, Qin N, Zhou W, Ma H, Jin G, et al. A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer. Cancer Med. 2018;7(6):2783–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim acta; Int J Clin Chem. 2018;487:363–8.
Article
CAS
Google Scholar
Chen S, Li T, Zhao Q, Xiao B, Guo J. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim acta; Int J Clin Chem. 2017;466:167–71.
Article
CAS
Google Scholar
Qiao GL, Chen L, Jiang WH, Yang C, Yang CM, Song LN, et al. Hsa_circ_0003998 may be used as a new biomarker for the diagnosis and prognosis of hepatocellular carcinoma. OncoTargets and therapy. 2019;12:5849–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ye DX, Wang SS, Huang Y, Chi P. A 3-circular RNA signature as a noninvasive biomarker for diagnosis of colorectal cancer. Cancer Cell Int. 2019;19:276.
Article
PubMed
PubMed Central
Google Scholar
Zhang Y, Wang Q, Zhu D, Rong J, Shi W, Cao X. Up-regulation of circ-SMAD7 inhibits tumor proliferation and migration in esophageal squamous cell carcinoma. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2019;111:596–601.
Article
CAS
Google Scholar
Kong Z, Wan X, Lu Y, Zhang Y, Huang Y, Xu Y, et al. Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. J Cell Mol Med. 2020;24(1):799–813.
Article
CAS
PubMed
Google Scholar
Jessmon P, Boulanger T, Zhou W, Patwardhan P. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev anticancer therapy. 2017;17(5):427–37.
Article
CAS
Google Scholar
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657–64.
Article
PubMed
Google Scholar
Guo B, Lian W, Liu S, Cao Y, Liu J. Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer. Oncol Lett. 2019;17(6):5523–8.
CAS
PubMed
PubMed Central
Google Scholar
Alcázar JL, Utrilla-Layna J, Mínguez J, Jurado M. Clinical and ultrasound features of type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23(4):680–4.
Article
PubMed
Google Scholar
Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD. Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer. 2008;18(3):465–9.
Article
CAS
PubMed
Google Scholar
Xu Q, Deng B, Li M, Chen Y, Zhuan L. circRNA-UBAP2 promotes the proliferation and inhibits apoptosis of ovarian cancer though miR-382-5p/PRPF8 axis. J Ovarian Res. 2020;13(1):81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer. Mol cancer. 2019;18(1):144.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao Y, Hu Y, Shen Q, Chen Q, Zhu XJ, Jiang SS, et al. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652. Eur Rev Med Pharmacol Sci. 2020;24(10):5281–91.
CAS
PubMed
Google Scholar
Liu ZH, Liu WJ, Yu XY, Qi XL, Sun CC. Circ_0005276 aggravates the development of epithelial ovarian cancer by targeting ADAM9. Eur Rev Med Pharmacol Sci. 2020;24(20):10375–82.
PubMed
Google Scholar
Chen S, Wu W, Li QH, Xie BM, Shen F, Du YP, et al. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. Cell death discovery. 2021;7(1):22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yan H, Xiang H, Sun B, Feng F, Chen P. Circular RNA-ITCH Inhibits the Proliferation of Ovarian Carcinoma by Downregulating lncRNA HULC. Reproductive sciences (Thousand Oaks. Calif). 2020;27(1):375–9.
CAS
Google Scholar
Ghaemmaghami F, Karimi Zarchi M, Hamedi B. High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Archives of gynecology and obstetrics. 2007;276(5):559–61.
Article
PubMed
Google Scholar
Wu HB, Shao K, Wang YC, Wang XC, Liu HL, Xie YT, et al. Research progress of CA125 and BDNF in serum of patients with acute myocardial infarction for predicting acute heart failure. Clin Hemorheol Microcirc. 2020;75(1):99–106.
Article
CAS
PubMed
Google Scholar
Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. Bjog. 2016;123(11):1761–8.
Article
CAS
PubMed
Google Scholar
Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE, et al. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2019;33(1):e22624.
Article
PubMed
Google Scholar
Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135–44.
Article
PubMed
Google Scholar
Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomedical Rep. 2016;5(1):41–4.
Article
CAS
Google Scholar
Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. 2016;9(1):43.
Article
PubMed
PubMed Central
Google Scholar